Glenmark Life Sciences Ltd
BSE: 543322
values in crores
Revenue & Profit Trend
in croresRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|---|
| INCOME | |||||||
| Revenue | 689.12+2.4% | 672.89+14.4% | 587.98-2.3% | 601.85-7.3% | 649.54+1.2% | 641.84+26.6% | 506.88 |
| Other Income | 22.78+63.5% | 13.93-5.4% | 14.72+63.8% | 8.98-10.9% | 10.09-3.5% | 10.46+22.6% | 8.53 |
| Total Income | 711.89+3.7% | 686.82+14.0% | 602.70-1.3% | 610.83-7.4% | 659.63+1.1% | 652.30+26.6% | 515.41 |
| EXPENSES | |||||||
| Expenditure | 496.10+7.2% | 462.77+8.0% | 428.56-4.3% | 447.85-4.4% | 468.34+0.3% | 467.15+20.4% | 387.96 |
| Tax | 53.14+10.4% | 48.13+9.1% | 44.11+6.4% | 41.45-16.1% | 49.42+2.6% | 48.19+49.9% | 32.14 |
| PROFIT | |||||||
| PBT | 215.80+8.8% | 198.39+13.9% | 174.14+6.8% | 162.98-14.8% | 191.29+3.3% | 185.15+45.3% | 127.46 |
| Net Profit | 162.66+8.3% | 150.26+15.6% | 130.03+7.0% | 121.53-14.3% | 141.87+3.6% | 136.96+43.7% | 95.32 |
| KEY METRICS | |||||||
| OPM % | 31.13%+0.57pp | 30.56%+0.09pp | 30.47%+1.84pp | 28.63%-1.92pp | 30.55%+5.77pp | 24.78%-0.37pp | 25.15% |
| NPM % | 22.85%+0.97pp | 21.88%+0.31pp | 21.57%+1.67pp | 19.90%-1.61pp | 21.51%+0.51pp | 21.00%+2.19pp | 18.81% |
| EPS | 13.23+8.0% | 12.25+15.6% | 10.60+7.0% | 9.91-14.3% | 11.57+3.5% | 11.18+1333.3% | 0.78 |
Corporate Events
Board MeetingGLS
202424Oct
Board Meeting
Consider and approve the Unaudited Financial Results
BSE Filing ↗ Board MeetingGLS
202423Jan
Board Meeting
Consider and approve the Unaudited Financial Results for the…
BSE Filing ↗ Board MeetingGLS
202320Oct
Board Meeting
Consider and approve Unaudited Financial Results for the sec…
BSE Filing ↗ Board MeetingGLS
20239Oct
Board Meeting
Consideration and approval of interim dividend for the finan…
BSE Filing ↗